Sio Capital Management, LLC In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Sio Capital Management, LLC reported 35 stock positions worth $223.1 million . Its top holding was Labcorp (LH) at 17.4% of the portfolio, followed by Teva Pharmaceutical-SP ADR (TEVA, 10.9% ) and Maximus (MMS, 6.5% ). Compared with Q2 2024, it opened 8 new positions, sold out of 16, added to 3 and reduced 13. The biggest buy was a new position in Teva Pharmaceutical-SP ADR (TEVA) and the biggest sale an exit from Smith & Nephew PLC -Spon ADR (SNN).
Location NEW YORK, NY
CIK 0001482416
Portfolio Value $223.1M (Q3 2024) Holdings 35 stocks · $223.1M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q2 2024 LH Labcorp Holdings Inc. 173,293 $38.7M Reduce -29.5% TEVA Teva Pharmaceutical-SP ADR 1,349,274 $24.3M New MMS Maximus Inc. 155,142 $14.5M New ZBH Zimmer Biomet Holdings Inc. 127,511 $13.8M Reduce -17.9% VXRT Vaxart Inc. 13,608,244 $11.6M Reduce -7.8% KVUE Kenvue Inc. 474,741 $11.0M Reduce -2.1% TFX Teleflex Inc. 39,272 $9.7M Reduce -64.6% TYRA Tyra Biosciences Inc. 400,870 $9.4M Reduce -33.2% IRON Disc Medicine Inc. 187,941 $9.2M Reduce -2.1% CI The Cigna Group 26,503 $9.2M Reduce -1.1% ANNX Annexon Inc. 1,433,155 $8.5M New BDSX Biodesix Inc. 4,338,514 $7.7M Reduce -0.2% RLAY Relay Therapeutics Inc. 945,839 $6.7M New ERAS Erasca Inc. 2,219,186 $6.1M Reduce -22.8% CMPS Compass Pathways PLC 914,639 $5.8M Add +211.7% ATXS Astria Therapeutics Inc. 504,887 $5.6M Reduce -1.1% PMVP PMV Pharmaceuticals Inc. 3,214,239 $4.8M Add +18.7% VTYX Ventyx Biosciences Inc. 1,971,948 $4.3M Add +153.2% IDYA Ideaya Biosciences Inc. 123,000 $3.9M New AORT Artivion Inc. 121,178 $3.2M New CRGX Cargo Therapeutics Inc. 173,860 $3.2M New CNTX Context Therapeutics Inc. 1,328,352 $2.6M No change ENTA Enanta Pharmaceuticals Inc. 177,004 $1.8M No change NUVB Nuvation Bio Inc. 668,115 $1.5M No change FHTX Foghorn Therapeutics Inc. 121,672 $1.1M No change XFOR X4 Pharmaceuticals Inc. 1,303,508 $872K Reduce -47.9% APRE Aprea Therapeutics Inc. 276,603 $761K No change AVTX Avalo Therapeutics Inc. 71,458 $679K No change RAPT THERAPEUTICS INC 315,000 $633K No change BOLD Boundless Bio Inc. 162,058 $562K No change NYXH Nyxoah SA 50,839 $486K No change VSTM Verastem Inc. 133,412 $399K No change MODULAR MED INC 120,772 $272K Reduce -92.2% NXTC Nextcure Inc. 130,000 $178K No change TERN Terns Pharmaceuticals Inc. 10,000 $83K New
Options reported separately and not counted above: ISRG puts ($29.0M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $118K (not counted above) Security Class Shares / Principal Value Change HUMAW Humacyte Inc.-CW27 *W EXP 08/27/202 49,998 $89K No change RCKTW Rocket Pharmaceuticals in-27 *W EXP 09/02/202 400,000 $29K No change CMXWQ Caremax-CW *W EXP 06/08/202 12,808 $108 No change
Total filed on the 13F, all lines: $223.2M.
Portfolio Sells Q2 2024 → Q3 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▲ SNN Smith & Nephew PLC -Spon ADR Sold out 0.00% −5.42 OGN Organon & Co. Sold out 0.00% −4.75 GSK GSK PLC-Spon ADR Sold out 0.00% −4.53 TFX Teleflex Inc. Reduce -64.6% 4.35% −4.46 CRBP Corbus Pharmaceuticals Holdi Sold out 0.00% −3.84 ABT Abbott Laboratories Sold out 0.00% −3.51 ANIP Ani Pharmaceuticals Inc. Sold out 0.00% −1.72 BLCO Bausch + Lomb Corp. Sold out 0.00% −1.66 ZYME Zymeworks Inc. Sold out 0.00% −1.58 LH Labcorp Holdings Inc. Reduce -29.5% 17.36% −1.52 BBIO Bridgebio Pharma Inc. Sold out 0.00% −1.20 APGE Apogee Therapeutics Inc. Sold out 0.00% −1.16 STOK Stoke Therapeutics Inc. Sold out 0.00% −0.89 THRD Third Harmonic Bio Inc. Sold out 0.00% −0.80 MODULAR MED INC Reduce -92.2% 0.12% −0.80 SPRY Ars Pharmaceuticals Inc. Sold out 0.00% −0.70 ARQT Arcutis Biotherapeutics Inc. Sold out 0.00% −0.56 PRLD Prelude Therapeutics Inc. Sold out 0.00% −0.46 ZBH Zimmer Biomet Holdings Inc. Reduce -17.9% 6.17% −0.19 XFOR X4 Pharmaceuticals Inc. Reduce -47.9% 0.39% −0.16 ASLAN PHARMACEUTICALS LTD Sold out 0.00% −0.03 ERAS Erasca Inc. Reduce -22.8% 2.72% +0.16 TYRA Tyra Biosciences Inc. Reduce -33.2% 4.22% +0.60 ATXS Astria Therapeutics Inc. Reduce -1.1% 2.49% +0.74 CI The Cigna Group Reduce -1.1% 4.12% +0.78 IRON Disc Medicine Inc. Reduce -2.1% 4.14% +0.88 BDSX Biodesix Inc. Reduce -0.2% 3.46% +0.95 VXRT Vaxart Inc. Reduce -7.8% 5.18% +1.46 KVUE Kenvue Inc. Reduce -2.1% 4.92% +1.60
Portfolio Buys Q2 2024 → Q3 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▼ TEVA Teva Pharmaceutical-SP ADR New 10.90% +10.90 MMS Maximus Inc. New 6.48% +6.48 ANNX Annexon Inc. New 3.80% +3.80 RLAY Relay Therapeutics Inc. New 3.00% +3.00 CMPS Compass Pathways PLC Add +211.7% 2.58% +1.91 IDYA Ideaya Biosciences Inc. New 1.75% +1.75 AORT Artivion Inc. New 1.45% +1.45 CRGX Cargo Therapeutics Inc. New 1.44% +1.44 VTYX Ventyx Biosciences Inc. Add +153.2% 1.93% +1.25 PMVP PMV Pharmaceuticals Inc. Add +18.7% 2.15% +0.49 TERN Terns Pharmaceuticals Inc. New 0.04% +0.04
Options Activity Q2 2024 → Q3 2024 Security Type Change vs Q2 2024 Underlying Shares Value ▼ INSM Insmed Inc. put Sold out 1,362,700 $91.3Mbefore exit ISRG Intuitive Surgical Inc. put New 59,000 $29.0M PCRX Pacira Biosciences Inc. put Sold out 455,500 $13.0Mbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 55 $583.5M AVR, COR, MMS, ALLO, GMED Q1 2026 71 $693.9M MMS, WAY, ICLR, COR, DNTH Q4 2025 63 $603.1M CELC, CI, SNY, MMS, ZBH Q3 2025 49 $395.1M MMS, CELC, SNY, DNTH, ALKS Q2 2025 47 $249.1M MMS, IRON, GMED, CNC, MRK Q1 2025 51 $330.2M ICLR, MMS, MRK, ZBH, NBIX Q4 2024 49 $355.3M ICLR, MMS, CI, LH, SNY Q3 2024 35 $223.1M LH, TEVA, MMS, ZBH, VXRT Q2 2024 43 $265.1M LH, TFX, ZBH, SNN, OGN Q1 2024 45 $287.0M LH, CI, GMED, MDGL, GSK